Announcement of the Resolution of the 23rd Board of Directors of the 10th Session of Harbin Pharmaceutical Group Co., Ltd.

Securities code: 600664 Securities abbreviation: Harbin Pharmaceutical Group Co., Ltd. Number: 2026-003 Harbin Pharmaceutical Group Co., Ltd.

Announcement of Resolutions of the 23rd Board of Directors of the 10th Session

The company's board of directors and all directors guarantee that there are no false records, misleading statements or major omissions in the announcement content, and assume legal responsibility for the authenticity, accuracy and completeness of its content.

The 23rd meeting of the 10th Board of Directors of Harbin Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") was notified in writing and was held by communication voting on January 26, 2026. Nine directors were supposed to attend the meeting, but nine directors actually attended the meeting. The meeting was held in compliance with the relevant provisions of the "Company Law of the People's Republic of China" and the "Articles of Association". The meeting reviewed and approved the "Proposal on the Company's Daily Related Transactions in 2026" (5 votes in favor, 0 votes against, 0 abstentions, related directors Ms. Hu Xiaoping, Mr. Sun Zhifeng, Mr. Yin Shiwei, and Mr. Liu Mo abstained from voting)

After deliberation, the company's board of directors agreed that the company expects the total amount of daily related transactions with related parties in 2026 to be 51.929 million yuan. Among them, the sales of various products and commodities produced or operated by the company to Harbin Pharmaceutical Group Co., Ltd. shall not exceed 4.3083 million yuan, and the provision of labor services to Harbin Pharmaceutical Group Co., Ltd. shall not exceed 1.05 million yuan; the sales of various products and commodities produced or operated by the company to Harbin Pharmaceutical Group Co., Ltd. shall not exceed 100,000 yuan; the purchase of various products and commodities produced or operated by GNC HOLDINGS, LLC, and the payment of royalties shall not exceed 4,632.07 Ten thousand yuan; donating various products and commodities produced or operated by the company to Heilongjiang Harbin Pharmaceutical Charity Foundation shall not exceed 150,000 yuan.

For details, please refer to the "Announcement of Harbin Pharmaceutical Group Co., Ltd. on the Estimated Daily Related Transactions in 2026" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on the same day.

This proposal has been reviewed and approved by the independent directors at the first special meeting in 2026.

Announcement is hereby made.

Board of Directors of Harbin Pharmaceutical Group Co., Ltd.

January 27, 2026